Evidence map›Paper›PMID 34035469›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021

Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu

Max E Joffe, Chiaki I Santiago, Sheryl Anne D Vermudez, Nicole M Fisher, Shalini Dogra, Colleen M Niswender, P Jeffrey Conn

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Advances in translating mGluPharmacology, biochemistry, and behavior · 2022
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Max E Joffe *Department of Pharmacology, Vanderbilt University, Nashville, TN, USA. max.joffe@vanderbilt.edu.
Chiaki I Santiago *Vanderbilt University, Nashville, TN, USA.
Sheryl Anne D VermudezDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Nicole M FisherDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Shalini DograDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA. jeff.conn@vanderbilt.edu.ORCID http://orcid.org/0000-0003-2363-0323
Vanderbilt University · US

Funding

TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lea K Davis · 2020 to 2026
$10.3M
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2M
Functions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5M
Postdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0M
Sex differences in fast-spiking interneurons promote AUD-related PFC dysfunction: remediation by modulating mGlu1 and mGlu5K99AA027806 · NIAAA · VANDERBILT UNIVERSITY · PI JOFFE, MAX E · 2020 to 2021
$276k
Stratifying Rett syndrome patient populations to evaluate the efficacy of genetic and pharmacological therapeutic interventionsF31MH119699 · NIMH · VANDERBILT UNIVERSITY · PI VERMUDEZ, SHERYL ANNE DAGUIMOL · 2019 to 2021
$91k
Metabotropic Glutamate Receptor 7 as a Novel Therapeutic Target for MECP2 Duplication SyndromeF31MH113259 · NIMH · VANDERBILT UNIVERSITY · PI FISHER, NICOLE MARIE · 2017 to 2019
$88k
NIAAA NIH HHS K99 AA027806NICHD NIH HHS P50 HD103537NIGMS NIH HHS T32 GM007628NIMH NIH HHS F31 MH113259NIMH NIH HHS F31 MH119699NIMH NIH HHS R01 MH062646NIMH NIH HHS T32 MH093366NINDS NIH HHS R01 NS031373NINDS NIH HHS R37 NS031373
6 · The paper itself

Abstract

Clinical and translational studies suggest that prefrontal cortex (PFC) dysregulation is a hallmark feature of several affective disorders. Thus, investigating the mechanisms involved in the regulation of PFC function and synaptic plasticity could aid in developing new medications. In recent years, the mGlu

Indexed as

Glutamic AcidAnimalsMiceNeuronal PlasticityPrefrontal CortexPyramidal CellsReceptors, Metabotropic GlutamateGlutamic Acidmetabotropic glutamate receptor 3Receptors, Metabotropic Glutamate

Identifiers

PMID34035469
PMCPMC8505649
OpenAlexW3165713600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.